AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02537002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous dose of matched placebo
Trial: NCT03858725
Drug: D569 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D569 Tab. 1T single oral administration under fasting condition
Trial: NCT03858725
Drug: CKD-374 5mg Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-374(Tofacitinib) 5mg Tab. 1T single oral administration under fasting condition
Trial: NCT01185743
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo td
Trial: NCT03560804
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
Trial: NCT02183272
Drug: Intranasal Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation.
Trial: NCT03676504
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 days of cyclophosphamide 500 mg/m\^2/day
Trial: NCT04373967
Drug: Victoza®.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Victoza®. Both products will be provided as pen-injector.
Trial: NCT04373967
Drug: TQZ2451
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive TQZ2451.Both products will be provided as pen-injector.
Trial: NCT02458768
Drug: IVF-M HP Inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02458768
Drug: Menopur® Inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00402571
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02850822
Drug: Chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen,such as CAG, G-CSF 5-10ug/kg/day on days 4 and 17；Aclacinomycin 7mg/m2/day on days 4 and 11；Cytarabine 20mg/m2/day on days 4 and 17.
Trial: NCT04144088
Drug: Wu Ling San
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.
Trial: NCT04144088
Drug: Yin-Chen Wu Ling San
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.
Trial: NCT04144088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.
Trial: NCT02047656
Drug: LFF269
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LFF269 capsules twice daily (b.i.d)
Trial: NCT02047656
Drug: Placebo to LFF269
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo LFF269 b.i.d for 10 days in healthy volunteers
Trial: NCT01935856
Drug: KHK7580
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02287584
Drug: DSP-5423P Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily
Trial: NCT02287584
Drug: DSP-5423P Placebo-to-Flex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSP-5423P Placebo:~DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily
Trial: NCT02287584
Drug: DSP-5423P Active-to-Flex
RxNorm normalized name: Ed Flex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSP-5423P Active:~DSP-5423P 40mg or 80mg was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily
Trial: NCT00106184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1
Trial: NCT03403751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion of 0.5 mL/kg of 0.9% saline (volume equivalent to Reltecimod dosing schema) over approximately 10 minutes
Trial: NCT02673866
Drug: DS-1971a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02673866
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04203043
Drug: Pycnogenol Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pycnogenol use to prevent hyper pigmentation after foam sclerotherapy
Trial: NCT02179502
Drug: GLPG1690 single ascending doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg
Trial: NCT02179502
Drug: GLPG1690, multiple ascending doses, oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg
Trial: NCT04003792
Drug: FOLFIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: systemic FOLFIRI chemotherapy
Trial: NCT00744549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day with meals.
Trial: NCT03062072
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy containing glucocorticoid as anti-emetics or anti-cancer agent except for targeted agents
Trial: NCT00069706
Drug: AL-12182 0.01% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Trial: NCT00069706
Drug: AL-12182 0.03% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Trial: NCT02764801
Drug: Ultrasound contrast agent (Contrast-enhanced ultrasound)
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.
Trial: NCT01292694
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, single administration, gelatin capsule filled with microcrystalline cellulose
Trial: NCT00742508
Drug: SK&F-105517-D 10 mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule once a day
Trial: NCT00742508
Drug: SK&F-105517-D 20 mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule once a day
Trial: NCT00742508
Drug: SK&F-105517-D 40 mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 2 capsule(s) once a day
Trial: NCT02178306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Run-in phase
Trial: NCT02046395
Drug: amlodipine, hydralazine, terazosin or hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure.
Trial: NCT02648854
Drug: CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered CKD-395 0.5/1000mg 1T to oral (fasting condition)
Trial: NCT02648854
Drug: CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)
Trial: NCT00003829
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03886779
Drug: Bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.7 MG/ML \[Prolensa\]
Trial: NCT03886779
Drug: Nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 MG/ML \[Ilevro\]
Trial: NCT00721279
Drug: Sifrol® (pramipexole dihydrochloride)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02715505
Drug: Umbilical cord blood transplantation with HSC835
RxNorm normalized name: cow umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835
Trial: NCT00346047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corresponding placebo is applied for 12weeks
Trial: NCT00710684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to existing donepezil
Trial: NCT02720263
Drug: ASP4345
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03429751
Drug: 30 ml/Kg/h crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 30 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
Trial: NCT03429751
Drug: 10 ml/Kg/h crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 10 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
Trial: NCT02338297
Drug: EGM
RxNorm normalized name: EGMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)
Trial: NCT03339726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 doses of placebo capsule and tablet taken 4 hours apart
Trial: NCT01092403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily by inhalation
Trial: NCT00983294
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.
Trial: NCT03558152
Drug: UTTR1147A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.
Trial: NCT03558152
Drug: UTTR1147A Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.
Trial: NCT02441270
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02730377
Drug: alpha-glucosidase inhibitors
RxNorm normalized name: alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Trial: NCT02730377
Drug: meglitinides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Trial: NCT02730377
Drug: sulphonylurea
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Trial: NCT02730377
Drug: thiazolidinediones
RxNorm normalized name: Thiazolidinediones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Trial: NCT01715974
Drug: GM-CSF group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 micrograms/day of GM-CSF from the day of embryo transfer through the day of beta HCG test
Trial: NCT02111746
Drug: Patient Controlled Analgesia (PCA)
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day
Trial: NCT00438243
Drug: Bromfenac (Xibrom)
RxNorm normalized name: bromfenac Ophthalmic Solution [Xibrom]
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop to affected eye twice daily.
Trial: NCT04401761
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 - 100 mg once daily at the discretion of the investigator
Trial: NCT02643862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00006825
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04772846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablets
Trial: NCT00758459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing to match AZD1236
Trial: NCT01572025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo containing no active ingredient. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)
Trial: NCT00961025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03384784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.
Trial: NCT03113123
Drug: PrEP with Truvada®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Associated with:~* STD screening/treatment for syphilis, gonorrhoea and chlamydiae~* HIV screening/therapy~* Questionnaire~* Addiction, social or psychological follow-up care if needed~* Peer interactive counselling (peer counselors/nurses/physicians experienced with therapeutic education) at the baseline visit and at every follow-up visit up to 6 months. After 6 months, counselling will be provided at the request of participants if they need it. Counselors will remain in contact with the participants between visit to answer any questions relative to PrEP, treatment and prevention, and to facilitate participants interactions with study sites.
Trial: NCT01849068
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 12 weeks
Trial: NCT01291537
Drug: best médical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00617695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01908465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01306318
Drug: eperisone hydrochloride plus diclofenac sodium capsule
RxNorm normalized name: diclofenac sodium Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given in healthy volunteers in fasting conditions
Trial: NCT01306318
Drug: eperisone hydrochloride tablet and diclofenac sodium tablet
RxNorm normalized name: diclofenac Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of eperisone hydrochloride 50 mg as tablet formulation and diclofenac sodium 50 mg as tablet formulation to be given in healthy volunteers in fasting conditions
Trial: NCT01532336
Drug: NVC-422 Solution, 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVC-422 Ophthalmic Solution dropped onto the eye
Trial: NCT01532336
Drug: NVC-422 Vehicle Solution
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVC-422 Vehicle Ophthalmic Solution dropped onto the eye
Trial: NCT00585013
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
Trial: NCT00922467
Drug: NaCl 9/00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same volume as in the esmolol group
Trial: NCT01928342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule without coenzyme A.
Trial: NCT00963924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
Trial: NCT00524069
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03586674
Drug: Ursogal
RxNorm normalized name: Ursogal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suspension
Trial: NCT00545961
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mixture, 0.28125 ml/kg twice a day for 7 days
Trial: NCT02807428
Drug: AYX1 Injection 660 mg/6 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mL solution for intrathecal injection with 660 mg of AYX1 (Brivoligide)
Trial: NCT02807428
Drug: Placebo Injection 6 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mL solution for intrathecal injection; vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Trial: NCT01413789
Drug: Dermatix
RxNorm normalized name: Dermatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 application of Dermatix
Trial: NCT01413789
Drug: Kelocote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 application of Kelocote
Trial: NCT00717314
Drug: CNI (≥75%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≥75% reduction from BL
Trial: NCT01413789
Drug: Alhydran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 application of Alhydran
Trial: NCT01413789
Drug: Bap Scar Care T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 application of BAP Scar Care T
Trial: NCT01413789
Drug: Bap Scar Care S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Application of Bap Scar Care S
Trial: NCT01413789
Drug: Mepiform
RxNorm normalized name: DRESSING,MEPIFORM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 application of Mepiform
Trial: NCT01413789
Drug: Scar Ban Elastic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 application of Scar Ban Elastic
Trial: NCT00661206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized in this group will receive placebo for 6 months.
Trial: NCT03788226
Drug: POF
RxNorm normalized name: Ta-Poff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
Trial: NCT00836537
Drug: Lotensin® 40 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 40 mg, single-dose fed
Trial: NCT03845881
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
Trial: NCT01506765
Drug: N-Acetyl-Cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
Trial: NCT02071862
Drug: CB-839
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB-839 monotherapy
Trial: NCT02071862
Drug: Pac-CB
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB-839 in combination with standard dose paclitaxel
Trial: NCT02071862
Drug: CB-Erl
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB-839 in combination with standard dose erlotnib
Trial: NCT02071862
Drug: CB-Cabo
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB-839 in combination with standard dose cabozantinib
Trial: NCT00765895
Drug: Placebo (for nortriptyline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for nortriptyline), 10 mg, one capsule, po qhs x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks;
Trial: NCT00263328
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 5 mg BID
Trial: NCT01910194
Drug: Luyxumia versus Lantus
FDA approved: no
EMA approved: no
PMDA approved: no